Coeptis Therapeutics (NASDAQ:COEP) Shares Set to Reverse Split on Tuesday, December 31st

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) are going to reverse split on the morning of Tuesday, December 31st. The 1-20 reverse split was announced on Friday, December 27th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 30th.

Coeptis Therapeutics Trading Down 13.6 %

Shares of NASDAQ:COEP traded down $0.03 during trading on Friday, reaching $0.18. 15,789,481 shares of the stock were exchanged, compared to its average volume of 1,243,014. The firm’s 50-day moving average price is $0.19 and its 200 day moving average price is $0.22. The firm has a market cap of $7.49 million, a price-to-earnings ratio of -0.63 and a beta of -0.90. Coeptis Therapeutics has a 12-month low of $0.13 and a 12-month high of $0.82. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.40 and a current ratio of 0.40.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.